Formoterol thrice weekly does not result in the development of tolerance to bronchoprotection, Pulsus Group Inc
CANADIAN RESPIRATORY JOURNAL
The Canadian Thoracic Society (CTS) Canadian Respiratory Health Professionals Canadian Critical Care Society (CCCS)

Note: (Optional)

Citation Builder

  •  
Return to Table of Contents
 
Original Article January/February 2003, Volume 10 Issue 1: 23-26
 

Formoterol thrice weekly does not result in the development of tolerance to bronchoprotection

BE Davis | JK Reid | DW Cockcroft

BACKGROUND: Loss of bronchoprotection routinely follows regular treatment with beta2-agonists. There are no data on the effects on bronchoprotection for thrice weekly use of a beta2-agonist.

METHODS: A double-blind, randomized, placebo controlled crossover trial was conducted to investigate the effects of thrice weekly administration of 12 mg of formoterol versus placebo on bronchoprotection against methacholine. As an expected positive control, formoterol 12 mg once daily was also evaluated.

RESULTS: There was no significant difference versus placebo in the bronchoprotective effects of 12 mg of formoterol administered on day 8, following daily treatment for seven days or treatment every other day (analysis of variance P=0.34). However, a nonsignificant trend towards lower concentration of methacholine that caused a 20% fall in forced expiratory volume in 1 s developed only following the daily formoterol dosing.

CONCLUSIONS: Thrice weekly dosing does not result in the development of tolerance to bronchoprotection against the direct acting stimulus methacholine.


Bronchoprotection | Formoterol
   Français   
          
Click to download PDF Reader
 
 




Copyright © Pulsus Group Inc.